The eclinical solutions market size is estimated to be USD 7,528.4 million in 2022 and is expected to witness a CAGR of 13.81% during the forecast period 2023-2033.  Expansion of biopharmaceutical and pharmaceutical firms’ research and development efforts and rising use of software solutions in clinical trials are factors contributing to the market growth. Additionally, strict regulatory framework for clinical trials and the increasing demand for safety monitoring and increasing Use of Software in Clinical Trials. However, high price of implementation is expected to hinder the growth.

Strict regulatory framework for clinical trials and the increasing demand for safety monitoring is expected to propel the market growth. For instance, United States Clinical trial registration requirements are being strengthened, and clinical data sharing is being encouraged, by the Department of Health and Human Services and the National Institutes of Health. One of the main growth drivers of the market for eClinical solutions is the soaring demand for software solutions for clinical trials by pharma and biopharma companies.

Increasing use of software in clinical trials is predicted to fuel the market growth. A rise in the use of eClinical solutions in clinical trials can be attributed to the need for recording and evaluating the growing amount of clinical data generated throughout clinical development procedures. Additionally, by eliminating redundant data entry, eClinical solutions enhance site performance, clinical trial efficiency, and cost optimization. Additionally, it is stated that the quick adoption of eClinical solutions, including RTSM, along with successful trial drug supply management, will encourage important corporations to raise their investment for product innovations.

Segmentation

By Product

The market is categorized into clinical analytics platform, safety solutions, electronic data capture & clinical data management systems, randomization & travel supply management, electronic clinical outcome assessment, clinical analytics platform, electronic trial master file, and clinical data integration platforms. In the global market, the electronic clinical outcome assessment segment accounted for the largest revenue share in 2022 owing to increasing necessity of high-quality clinical data. Using eCOA systems to collect data enhances the quality of the data collected, accelerates the data collecting process, and provides efficient data analysis. The key benefits of eCOA include the elimination of data variance risk, streamlined information, and reduced site monitoring costs. Its demand is anticipated to increase in the upcoming years due to the advantages mentioned above. Additionally, the requirement of integrating clinical research studies with patient care, which results in a more patient-centric approach, is anticipated to support the segment’s expansion.

By Delivery Mode

The market is divided into licensed enterprise, web-hosted, and cloud-based. In 2022, the web-hosted segments accounted for the highest revenue share due to benefits including ease of use, usability, and low initial investment. As web-hosted products are highly adaptable, providers can alter the way that information is presented to different user groups. The cloud-based segment is predicted to grow at an exponential CAGR throughout the projection period due to integrated features including flexibility, high accessibility, minimal handling costs, and simple data backup. These systems make real-time data available, allowing users to act rapidly and provide high-quality data for risk-based monitoring. The demand for cloud-based solutions is expected to increase as a result of these related benefits.

By Development Phase

The market is segregated into phase 1, phase 2, phase 3, and phase 4. In the global market, the phase 3 segment accounted for the largest revenue share in 2022 owing to increasing need for clinical data management software to reduce overall costs and boost process effectiveness. The expansion of the market is being significantly accelerated by the rising number of medicines that successfully complete phase III. Phase III involves evaluating a drug’s effectiveness on a group of more than 1,000 patients. The complexity of the study rises as the number of participants grows, which fuels the demand for computer-based data management systems and accelerates the use of eClinical solutions. The phase I segment is predicted to be the most viable segment throughout the forecast period due to the significance of these systems in predicting future outcomes and eliminating medicine candidates with the lowest chance of success.

By End Use

The market is segmented into CROs, pharma & biotech organizations, hospitals/healthcare providers, academic institutes, and medical device manufacturers. In 2022, the CROs segment accounted for the largest revenue share owing to pharmaceutical companies’ growing tendency to reduce total spending. The potential for segment growth is being further expanded by the growing use of eClinical technologies in research. The advantages of outsourcing clinical trials to CROs are the main driver of market’s rapid expansion. These advantages include lower costs, improved service efficiency, higher productivity, and a stronger emphasis on key development areas that are important to a company’s expansion. The pharma and biotech company segment is anticipated to expand significantly over the projected period due to researchers using eClinical solutions more frequently, which enhance clinical trials and reduce workloads.

Regional Markets

In 2022, North America region accounted for the highest revenue in the eclinical solutions market and is expected to maintain its dominance during the forecast period. This is attributed to the growing target population and the incidence of lifestyle-related diseases including diabetes and heart problems. The region’s market is also being driven by the introduction of new products by providers of eClinical solutions and an increase in government incentives. Additionally, it is projected that the residence of key players and the accessibility of sophisticated infrastructure will both augment the growth of the regional market. The market for eClinical solutions in Asia Pacific is anticipated to grow at a notable CAGR over the projection period. The demand for software solutions in this region is being fuelled by the region’s high unmet medical requirements and the increased prevalence of key chronic diseases including cancer, cardiovascular problems, and infectious diseases.

Competitor Insights

Some of the key players operating in the market are IBM Watson Health, Oracle, ERT Clinical, Parexel International Corporation, Anju Life Sciences Software, Dassault Systems, Bioclinica, CRF Health, Datatrak International, Inc., eClinical Works, and eClinical Solutions.

To achieve a competitive edge, these businesses are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by company in this sector.

• For instance, in order to provide innovative solutions to their customers and give them access to a more diverse and traditionally underrepresented population for their clinical trials, Parexel International Corporation and Signify Health partnered in January 2021. Additionally, ERT and Bioclinica declared their merger in December 2020. By joining up, ERT and Bioclinica aim to become industry leaders in clinical trial endpoint technologies.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including product, delivery mode, development phase, and end use from 2023 to 2033.

Report Scope:

Segmentation: eClinical Solutions Market Report 2022 – 2033

Product (Revenue, USD Million), 2022 – 2033

• Clinical Analytics Platform
• Safety Solutions
• Electronic Data Capture & Clinical Data Management Systems
• Randomization & Travel Supply Management
• Electronic Clinical Outcome Assessment
• Clinical Analytics Platform
• Electronic Trial Master File
• Clinical Data Integration Platforms

Delivery Mode (Revenue, USD Million), 2022 – 2033

• Licensed Enterprise
• Web-hosted
• Cloud-based

Development Phase (Revenue, USD Million), 2022 – 2033

• Phase 1
• Phase 2
• Phase 3
• Phase 4

End Use (Revenue, USD Million), 2022 – 2033

• CROs
• Pharma & Biotech Organizations
• Hospitals/Healthcare Providers
• Academic Institutes
• Medical Device Manufacturers

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA